Is it safe to combine bupropion (Wellbutrin) with lithium, and what dosing and monitoring guidelines should be followed?

Combining Bupropion (Wellbutrin) and Lithium

The combination of bupropion and lithium is generally safe and can be used together, particularly in patients with bipolar depression, but requires careful monitoring for seizure risk and neuropsychiatric symptoms. 1

Clinical Context and Evidence

The combination of bupropion and lithium has established clinical utility, particularly in treatment-resistant mood disorders. Lithium can be used to augment antidepressant drugs, including bupropion, with blood levels of 0.2 to 0.6 mEq/L generally adequate for augmentation (typically achieved with 150-300 mg daily). 1

Research evidence supports this combination:

• A double-blind trial demonstrated bupropion's efficacy in bipolar depression when added to lithium or anticonvulsants, with lower rates of mood elevation compared to tricyclic antidepressants 2
• Open studies in rapid-cycling bipolar II patients showed sustained improvement when bupropion was combined with lithium, without inducing hypomania 3
• Recent preclinical data suggests synergistic antidepressant effects between bupropion and lithium 4

Critical Safety Considerations

Seizure Risk (Primary Concern)

Bupropion lowers the seizure threshold and should not exceed 450 mg daily in bipolar patients. 5 The FDA label explicitly warns about seizure risk and advises patients to discontinue bupropion if seizures occur 6.

One case report documented prolonged seizure activity during ECT in a patient receiving bupropion, lithium, and venlafaxine concurrently 7, highlighting the importance of:

• Avoiding doses above 450 mg/day of bupropion
• Monitoring for factors that further lower seizure threshold
• Exercising extreme caution if ECT is planned (consider discontinuing bupropion)

Drug Interactions

Lithium clearance can be affected by medications that alter renal function 8. The FDA label for lithium notes that neuromuscular blocking agents should be given with caution, and that combined use with haloperidol has been associated with encephalopathic syndrome 9. However, no specific interaction between bupropion and lithium is documented in the FDA labels.

Neuropsychiatric Monitoring

Both medications carry neuropsychiatric warnings:

• Bupropion: Monitor for mood changes, psychosis, hallucinations, agitation, and suicidal ideation 6
• Lithium: At higher doses, elderly patients are prone to neurotoxicity 9

Dosing Algorithm

Bupropion Dosing

• Start: 37.5 mg every morning, increase by 37.5 mg every 3 days 1
• Maximum: 150 mg twice daily (300 mg/day total)
• Timing: Give second dose before 3 PM to minimize insomnia 1
• Do not exceed 450 mg/day in bipolar patients 5

Lithium Dosing for Augmentation

• Start: 150 mg daily 1
• Target level: 0.2-0.6 mEq/L (lower than typical maintenance levels of 0.6-0.8 mEq/L) 1, 10
• Typical dose: 150-300 mg daily achieves augmentation levels 1

Monitoring Requirements

Initial Phase

• Lithium levels: Check 5-7 days after dose changes, then weekly until stable
• Renal function: Baseline and regularly (creatinine, BUN)
• Thyroid function: Baseline TSH, monitor during stabilization 9
• Electrolytes: Ensure adequate sodium and fluid intake (2500-3000 mL daily) 9

Maintenance Phase

• Lithium levels: Every 3-6 months once stable 10
• Renal and thyroid function: Every 6-12 months 10
• Blood pressure and heart rate: Periodically, especially first 12 weeks 11
• Neuropsychiatric symptoms: Ongoing assessment for mood changes, suicidality, psychosis

Special Populations

Renal Impairment

• Moderate-severe renal impairment: Reduce lithium dose; avoid in end-stage renal disease 9
• Bupropion dose adjustment not specifically required but use caution

Hepatic Impairment

• Moderate-severe hepatic impairment: Maximum lithium 150 mg daily 9
• Use both medications cautiously in hepatic impairment

Elderly Patients

• Lower lithium targets (potentially 0.4-0.6 mEq/L) may be appropriate 10
• Increased neurotoxicity risk at higher lithium doses 1

Clinical Pitfalls to Avoid

1. Do not combine with other bupropion-containing products (Zyban, Aplenzin, generic formulations) 6
2. Do not use with MAO inhibitors (within 14 days) 6
3. Avoid in patients with seizure disorders or eating disorders 6
4. Monitor for lithium toxicity signs: diarrhea, vomiting, tremor, ataxia, drowsiness, weakness 9
5. Ensure adequate hydration and salt intake to prevent lithium toxicity 9
6. Counsel patients to report mood changes immediately, including depression worsening, mania, or suicidal thoughts 6

When to Consider This Combination

Preferentially use bupropion-lithium combination in:

• Treatment-resistant bipolar depression 5
• Rapid-cycling bipolar II disorder 3
• Patients requiring smoking cessation (bupropion has dual benefit) 11
• Patients with comorbid depression needing mood stabilization 1

Avoid this combination in:

• Active seizure disorder or history of seizures 6
• Uncontrolled hypertension (monitor carefully if used) 11
• Severe renal or hepatic impairment 9
• Patients requiring chronic opiate therapy (if using naltrexone-bupropion formulation) 11